Company profile for Genetix Biotherapeutics

NEW Drugs in Dev: 10
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Genetix Biotherapeutics is a privately held, commercial-stage biotechnology company dedicated to delivering curative genetic therapies for severe rare diseases. Formerly bluebird bio, the company has three FDA-approved, first-in-class gene therapies for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. These one-time treatments address the underlying cause of disease and provide durable benefit. Building o...
Genetix Biotherapeutics is a privately held, commercial-stage biotechnology company dedicated to delivering curative genetic therapies for severe rare diseases. Formerly bluebird bio, the company has three FDA-approved, first-in-class gene therapies for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. These one-time treatments address the underlying cause of disease and provide durable benefit. Building on decades of scientific innovation and clinical experience, Genetix is focused on expanding patient access and strengthening the treatment experience for patients, families and healthcare providers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
60 Binney St. Cambridge, MA 02142
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/business/bye-bye-bluebird-gene-therapy-biotech-emerges-from-private-buyout-with-rebrand

BIOSPACE
19 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-18/bluebird-bio-rebrands-as-genetix-biotherapeutics-returning-to-its-foundational-roots

PHARMAWEB
18 Sep 2025

https://www.fiercepharma.com/pharma/fda-restricts-bluebird-bio-gene-therapy-skysona-after-blood-cancer-reports

FIERCE PHARMA
12 Aug 2025

https://www.contractpharma.com/breaking-news/bluebird-bio-bolsters-management-team-with-appointments/

CONTRACTPHARMA
01 Jul 2025

https://www.businesswire.com/news/home/20250701329208/en/bluebird-bio-Strengthens-Leadership-Team-With-New-Appointments

BUSINESSWIRE
01 Jul 2025

https://www.businesswire.com/news/home/20250602288470/en/bluebird-bio-Announces-Completion-of-Acquisition-by-Carlyle-and-SK-Capital

BUSINESSWIRE
02 Jun 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty